Branded Legacy, Inc. (OTC: BLEG), a diversified holdings company in the health and wellness sector, has officially expanded its portfolio by acquiring Bio Legacy Evaluative Group, formerly known as Menlo Health. This all-stock transaction, valued at $1.5 million in Preferred D shares, was finalized on July 31, 2025. The acquisition signifies Branded Legacy's strategic move into the biotech and medical devices industry, aiming to tackle pressing global health issues such as the addiction epidemic and inefficiencies in vaccine distribution.
Under the leadership of CEO Amin Janmohamed, Bio Legacy Evaluative Group brings to the table a patented all-in-one intranasal naloxone device. This innovation is set to tap into a market expected to surge from $371 million in 2022 to over $1.16 billion by 2032. Additionally, Bio Legacy's technology for nasal delivery of vaccines and cold-chain therapies presents a promising avenue for enhancing vaccine distribution methods worldwide.
The deal includes several key components: performance-based conversion milestones, a two-year lock-up period, and a commitment to invest $1 million in research and development following the company's uplisting to OTCQB. This acquisition not only broadens Branded Legacy's operational scope but also underscores its commitment to innovation and addressing critical health challenges. For more details on the acquisition, visit https://ibn.fm/U7eSy.
Branded Legacy's foray into the biotech and medical devices sector through this acquisition is a testament to its forward-thinking approach and dedication to creating sustainable value for its shareholders. The company's focus on strategic growth and quality in the health and wellness sector is further solidified by this move, promising to enhance lives through innovative solutions. For further information about Branded Legacy, visit https://BrandedLegacy.com.
